BioSpace

Before GMP: Six manufacturing considerations gene therapy sponsors should address earlier

SK pharmteco’s Tatiana Nanda, chief technical officer of SK pharmteco Viral Vector North America discusses what gene therapy sponsors must account for sooner rather than later when preparing for GMP manufacturing.

By BioSpace

1 min read
Before GMP: Six manufacturing considerations gene therapy sponsors should address earlier
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights